Tamoxifen Citrate
产品编号: DC9180
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Tamoxifen(ICI-46474) is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(10.117), SARS-COV(11.696).
Cas No.: |
54965-24-1 |
名称: |
|
别名: |
|
SMILES: |
CN(CCOC1=CC=C(/C(=C(/C2=CC=CC=C2)\CC)/C2=CC=CC=C2)C=C1)C.O=C(CC(C([O-])=O)(O)CC([O-])=O)[O-] |
分子式: |
C32H37NO8 |
分子量: |
563.64 |
纯度: |
|
保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: |
|
In Vivo: |
|
In Vitro: |
|
References: |
Tamoxifen(ICI-46474) is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen.in vitro: 4-hydroxytamoxifen, the active metabolite of tamoxifen, estradiol and 13 estradiol metabolites were tested in concentrations ranging from 3.1 to 100 microM. Incubation time was 4 days and cell proliferation was measured by means of the ATP chemosensitivity test. 4-hydroxytamoxifen showed an IC50 value of 27 microM and 18 microM in MCF-7 and MDA-MB 231 cells, respectively. Tamoxifen failed to significantly inhibit T-47Daro spheroid cell proliferation over a 100-500 nM concentration range.
in vivo: 30 μg tamoxifen/g body weight/day injected on three consecutive days is the optimal condition for the αMHC-MerCreMer system to induce recombination in the Rosa26-lacZ strain. MAPK signaling can be transiently activated in the brain, liver, or kidney of Braf(V637E)ER(T2) mice by a single injection of tamoxifen. Braf(V637E)ER(T2) mice provide a new versatile tool to study disease mechanisms elicited by MAPK activation, complementing gene knockout technology that is restricted to the analysis of loss-of-function phenotypes. |
Kinase Assay: |
|
Cell Assay: |
|
Animal Administration: |
|
References: |
|
MSDS
COA
LOT NO. |
DOWNLOAD |
|
|
2018-0101 |
|
询盘